Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.15 Billion CNY | -34.39% |
| 2022 | 1.76 Billion CNY | 30.47% |
| 2021 | 1.35 Billion CNY | 2.99% |
| 2020 | 1.31 Billion CNY | 171.48% |
| 2019 | 483.45 Million CNY | -10.47% |
| 2018 | 540.01 Million CNY | 6.97% |
| 2017 | 504.81 Million CNY | 234.32% |
| 2016 | 150.99 Million CNY | 54.19% |
| 2015 | 97.92 Million CNY | 1.54% |
| 2014 | 96.44 Million CNY | 1.65% |
| 2013 | 94.87 Million CNY | -21.01% |
| 2012 | 120.12 Million CNY | 2.21% |
| 2011 | 117.52 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.18 Billion CNY | 3.53% |
| 2024 Q1 | 1.14 Billion CNY | -0.66% |
| 2024 Q2 | 1.14 Billion CNY | -0.56% |
| 2023 Q3 | 1.02 Billion CNY | -9.98% |
| 2023 Q1 | 1.17 Billion CNY | -33.58% |
| 2023 Q2 | 1.13 Billion CNY | -3.02% |
| 2023 FY | 1.15 Billion CNY | -34.39% |
| 2023 Q4 | 1.15 Billion CNY | 13.15% |
| 2022 Q3 | 1.6 Billion CNY | -12.12% |
| 2022 FY | 1.76 Billion CNY | 30.47% |
| 2022 Q2 | 1.82 Billion CNY | -18.17% |
| 2022 Q1 | 2.22 Billion CNY | 64.69% |
| 2022 Q4 | 1.76 Billion CNY | 10.16% |
| 2021 Q1 | 1.29 Billion CNY | -1.21% |
| 2021 FY | 1.35 Billion CNY | 2.99% |
| 2021 Q3 | 1.22 Billion CNY | -12.31% |
| 2021 Q2 | 1.4 Billion CNY | 8.16% |
| 2021 Q4 | 1.35 Billion CNY | 9.92% |
| 2020 Q1 | 1.01 Billion CNY | 109.41% |
| 2020 Q3 | 1.19 Billion CNY | 18.23% |
| 2020 Q4 | 1.31 Billion CNY | 9.46% |
| 2020 FY | 1.31 Billion CNY | 171.48% |
| 2020 Q2 | 1.01 Billion CNY | 0.17% |
| 2019 Q1 | 538.4 Million CNY | -0.3% |
| 2019 FY | 483.45 Million CNY | -10.47% |
| 2019 Q4 | 483.45 Million CNY | -0.55% |
| 2019 Q2 | 496.71 Million CNY | -7.74% |
| 2019 Q3 | 486.14 Million CNY | -2.13% |
| 2018 Q4 | 540.01 Million CNY | 17.02% |
| 2018 Q2 | 519.74 Million CNY | 1.15% |
| 2018 Q1 | 513.81 Million CNY | 1.78% |
| 2018 FY | 540.01 Million CNY | 6.97% |
| 2018 Q3 | 461.48 Million CNY | -11.21% |
| 2017 Q1 | 312.09 Million CNY | 106.69% |
| 2017 FY | 504.81 Million CNY | 234.32% |
| 2017 Q4 | 504.81 Million CNY | 2.5% |
| 2017 Q3 | 492.52 Million CNY | 34.97% |
| 2017 Q2 | 364.91 Million CNY | 16.93% |
| 2016 FY | 150.99 Million CNY | 54.19% |
| 2016 Q3 | 101.12 Million CNY | 1.44% |
| 2016 Q2 | 99.68 Million CNY | 14.29% |
| 2016 Q1 | 87.22 Million CNY | -10.93% |
| 2016 Q4 | 150.99 Million CNY | 49.31% |
| 2015 Q2 | 84.58 Million CNY | -1.37% |
| 2015 FY | 97.92 Million CNY | 1.54% |
| 2015 Q3 | 83.95 Million CNY | -0.74% |
| 2015 Q4 | 97.92 Million CNY | 16.64% |
| 2015 Q1 | 85.75 Million CNY | -11.08% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 96.44 Million CNY | 0.0% |
| 2014 FY | 96.44 Million CNY | 1.65% |
| 2013 FY | 94.87 Million CNY | -21.01% |
| 2012 FY | 120.12 Million CNY | 2.21% |
| 2011 FY | 117.52 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 85.58% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 77.873% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | 8.357% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | 20.431% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | -49.767% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | 23.259% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -88.073% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | 67.939% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -423.468% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | -14.94% |